Ozempic: What It Is, How It Works, and How It Compares to Wegovy, Mounjaro, and Zepbound

What exactly is Ozempic and what is it approved for?

Ozempic is a once-weekly subcutaneous injection of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The FDA approved it in December 2017 for glycemic control in adults with type 2 diabetes and, separately, to reduce the risk of major adverse cardiovascular events (MACE) in adults with T2D and established cardiovascular disease. It is not FDA-approved as a weight-loss medication. That indication belongs to Wegovy, which uses the same molecule at a higher maintenance dose of 2.4 mg per week.

GLP-1 receptors sit in the pancreas, brain, stomach, and heart. Semaglutide activates them to stimulate glucose-dependent insulin release, suppress glucagon, slow gastric emptying, and signal satiety to the hypothalamus [1]. The net effect is lower post-meal blood sugar and reduced caloric intake. Semaglutide's half-life is approximately 165 hours, which is why once-weekly dosing is sufficient [2].

Prescribers commonly use Ozempic off-label for weight management, a practice that is legal but sits outside the approved labeling. Patients seeking the weight-loss indication specifically should discuss Wegovy, Mounjaro, or Zepbound with their clinician.

How is Ozempic dosed and how do you take it?

Dosing follows a fixed titration ladder designed to minimize gastrointestinal side effects. Patients start at 0.25 mg once weekly for four weeks, then advance to 0.5 mg. If additional glycemic control is needed after at least four weeks, the dose increases to 1 mg, and a 2 mg dose is available for patients who require further lowering of HbA1c [3].

The injection goes into the abdomen, thigh, or upper arm. Day of the week does not matter as long as doses are at least 48 hours apart. Ozempic can be taken with or without food. Pens should be stored in the refrigerator before first use but may be kept at room temperature (below 30°C / 86°F) for up to 56 days after opening [3].

Patients who miss a dose may take it within five days of the scheduled day. Beyond five days, they skip that dose and resume their regular schedule the following week [3]. Starting a new dose level too quickly is the most common reason patients experience severe nausea, so clinicians are advised to hold titration for an extra four weeks if tolerability is a concern.

What do the clinical trials show about Ozempic's effectiveness?

The STEP trial program and the SELECT cardiovascular outcomes trial provide the strongest evidence base for semaglutide. Although several STEP trials used the 2.4 mg Wegovy dose, STEP-2 specifically examined the population most relevant to Ozempic prescribers: adults with type 2 diabetes.

In STEP-2 (N=1,210, published in The Lancet 2021), participants received semaglutide 2.4 mg, semaglutide 1 mg, or placebo for 68 weeks. The 1 mg group, which mirrors Ozempic dosing, achieved a mean weight reduction of 7.0% and an HbA1c drop of approximately 1.6 percentage points versus placebo [4]. The 2.4 mg group reached 9.6% weight loss and a 1.6-point HbA1c drop as well, demonstrating that additional weight reduction is achievable at higher semaglutide doses even in patients with T2D [4].

For cardiovascular outcomes, the SELECT trial (N=17,604, NEJM 2023) enrolled adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 20% versus placebo over a mean follow-up of 39.8 months (hazard ratio 0.80 to 95% CI 0.72, 0.90, P<0.001) [5]. This finding shaped the Wegovy label's cardiovascular indication in 2024 and reinforces the broader benefit of GLP-1 receptor agonist therapy in high-risk populations [1].

STEP-5 (N=304, Nature Medicine 2022) extended the observation window to 104 weeks. Participants on semaglutide 2.4 mg maintained a mean 15.2% body weight reduction at two years, compared with 2.6% on placebo, with no new safety signals emerging in the second year [6].

How does Ozempic compare to Wegovy?

Wegovy and Ozempic contain identical active ingredients. The difference is dose and approved indication. Wegovy's maintenance dose is 2.4 mg per week, reached after a 16-to-20-week titration. Ozempic's maximum approved dose is 2 mg per week [3][1].

In STEP-1 (N=1,961, NEJM 2021), adults with overweight or obesity without diabetes on semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks versus 2.4% on placebo [7]. That degree of weight loss exceeds what is typically seen with Ozempic's 1 mg or 2 mg doses in clinical practice. The FDA-approved Wegovy label specifies the 2.4 mg dose for chronic weight management [1].

For patients whose primary goal is glycemic control in T2D, Ozempic is the on-label choice. For patients with a BMI of 30 or higher (or BMI of 27 or higher with at least one weight-related comorbidity) whose primary goal is weight reduction, Wegovy is the labeled option. Insurance coverage often differs between the two pens despite the shared molecule, which can affect which prescription a clinician writes [1][3].

How does Ozempic compare to Mounjaro and Zepbound?

Mounjaro (tirzepatide) and Zepbound (tirzepatide) are manufactured by Eli Lilly. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor simultaneously. Mounjaro carries the T2D indication; Zepbound carries the obesity indication.

The SURMOUNT-1 trial (N=2,539, NEJM 2022) compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against placebo in adults with obesity without T2D. At 72 weeks, the 10 mg group achieved mean weight loss of 19.5% and the 15 mg group achieved 20.9%, versus 3.1% on placebo (P<0.001 for all doses) [8]. Those figures exceed what STEP-1 reported for semaglutide 2.4 mg (14.9%) in a comparable population, though the trials were not head-to-head comparisons and populations differed slightly.

SURMOUNT-2 (Lancet 2023) examined tirzepatide in adults with T2D and obesity. The 15 mg arm produced a mean 15.7% weight reduction and a 2.1-percentage-point HbA1c drop at 72 weeks [9]. Direct comparison with STEP-2 semaglutide data suggests a numerically larger effect, but no adequately powered randomized head-to-head trial between semaglutide and tirzepatide in T2D has been published as of early 2025.

SURMOUNT-4 (JAMA 2024) addressed what happens when tirzepatide is stopped. After 36 weeks of open-label tirzepatide, participants were randomized to continue or switch to placebo. Those who continued lost a further 5.5% of body weight at week 88, while those who stopped regained 14.8% [10]. This mirrors weight-regain data seen with semaglutide withdrawal and underscores that these medications treat a chronic condition requiring long-term management.

The Zepbound FDA label sets dosing at 2.5 mg weekly starter, titrated to 5 mg, 10 mg, or 15 mg over 20 weeks [11].

How does Ozempic compare to Saxenda?

Saxenda (liraglutide 3 mg) is an earlier Novo Nordisk GLP-1 agonist approved for chronic weight management. Unlike Ozempic and Wegovy, Saxenda requires daily injections. Its maximum approved dose is 3 mg subcutaneously each day [12].

The STEP-8 trial (N=338, JAMA 2022) was the first adequately powered direct head-to-head comparison of semaglutide 2.4 mg versus liraglutide 3 mg. At 68 weeks, semaglutide produced a mean 15.8% weight loss while liraglutide produced 6.4% (difference 9.4 percentage points, P<0.001) [12]. Semaglutide also outperformed liraglutide on every secondary endpoint including waist circumference, HbA1c, and patient-reported outcomes [12].

Saxenda has a role for patients who cannot tolerate weekly injections, who prefer daily dosing for psychological reasons, or who face cost barriers. However, on efficacy data alone, once-weekly semaglutide is the superior agent in direct comparison [12].

What are Ozempic's side effects and safety considerations?

Gastrointestinal events are the most common adverse effects. In STEP-2, nausea affected 39.9% of semaglutide 2.4 mg participants versus 12.6% on placebo; diarrhea affected 30.2% versus 15.7% [4]. Most events were mild to moderate and peaked during dose escalation before resolving. Slowing titration reduces incidence significantly.

Serious but rare risks include:

• Pancreatitis. Semaglutide carries a warning for acute pancreatitis. Clinicians should discontinue the drug if pancreatitis is confirmed [3].
• Thyroid C-cell tumors. Rodent studies showed C-cell hyperplasia at supratherapeutic doses. The FDA requires a black-box warning; Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3].
• Diabetic retinopathy complications. In SUSTAIN-6 to 3% of semaglutide participants experienced retinopathy complications versus 1.8% on placebo, possibly tied to rapid HbA1c reduction. Patients with pre-existing retinopathy warrant closer ophthalmologic follow-up [13].
• Gastroparesis/gastric stasis. Case reports of severe delayed gastric emptying have led to updated anesthesia guidelines recommending extended pre-procedure fasting for patients on GLP-1 agents [14].
• Hypoglycemia. Ozempic does not cause hypoglycemia by itself but may increase the risk when combined with insulin or sulfonylureas; dose reductions of those agents may be necessary [3].

Semaglutide is contraindicated in pregnancy. Women of childbearing potential should use reliable contraception. Because semaglutide slows gastric emptying, oral contraceptives may be absorbed more slowly; backup contraception is advisable during dose escalation [3].

Who is a candidate for Ozempic, and who should avoid it?

The AACE/ACE obesity clinical practice guidelines recommend pharmacotherapy as an adjunct to lifestyle modification in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one obesity-related comorbidity [15]. For patients who also carry a T2D diagnosis, Ozempic offers dual benefit: glycemic control plus cardiovascular risk reduction.

Contraindications include:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Prior serious hypersensitivity to semaglutide or any excipient
• Pregnancy or planned pregnancy within two months of last dose [3]

Patients with severe renal impairment (eGFR <15 mL/min/1.73 m²) may use semaglutide without dose adjustment per the current label, though close monitoring is recommended [3]. Patients with prior pancreatitis should discuss the risk-benefit profile with their clinician before starting any GLP-1 agent.

The HealthRX clinical team uses a three-question pre-prescription screen for Ozempic candidates: (1) Does the patient have T2D or established CVD that makes the labeled indications applicable? (2) Is the primary goal glycemic control, cardiovascular protection, or weight loss? (3) Has the patient's BMI and comorbidity profile been mapped against the Wegovy, Zepbound, or Saxenda labels to determine whether a different agent is more appropriate? This screen routes most pure-obesity patients without T2D toward the obesity-labeled drugs while reserving Ozempic for its approved indications.

What does Ozempic cost, and is it covered by insurance?

The list price for a monthly supply of Ozempic pens runs approximately $935, $998 depending on dose, as of early 2025. Most commercial insurance plans cover Ozempic for the T2D indication, though prior authorization is common. Coverage for off-label weight loss use is frequently denied. Medicare Part D covers Ozempic for T2D but, as of 2025, generally excludes weight-loss-only prescriptions [3].

Novo Nordisk's savings card program may reduce out-of-pocket costs to as low as $25 per month for eligible commercially insured patients. Patients on government insurance programs do not qualify [3]. Compounded semaglutide from 503B outsourcing facilities became widely available during the FDA shortage period; the FDA removed semaglutide from its drug shortage database in early 2025, which may narrow access to compounded versions going forward.

SURMOUNT-3 (Nature Medicine 2023, N=579) provided indirect cost-effectiveness context by demonstrating that tirzepatide produced an additional 18.4% weight reduction after a 12-week intensive lifestyle intervention, meaning behavioral therapy combined with pharmacotherapy outperforms either approach alone regardless of agent chosen [16]. This finding supports the standard clinical practice of pairing any GLP-1 drug with structured dietary and exercise counseling.

What happens if you stop taking Ozempic?

Weight and glycemic control returns toward baseline after discontinuation. STEP-5 data showed that participants who completed 104 weeks on semaglutide 2.4 mg and then discontinued regained most of the lost weight within one year [6]. SURMOUNT-4 showed similar rebound with tirzepatide: stopping after 36 weeks led to 14.8% weight regain by week 88 [10].

HbA1c also rises when Ozempic is stopped. Patients with T2D who discontinue should have a plan for alternative glycemic management, whether through another antidiabetic agent or intensified lifestyle intervention. The American Diabetes Association Standards of Care classify GLP-1 receptor agonists as preferred agents in T2D patients with established or high-risk cardiovascular disease precisely because abrupt discontinuation in this population carries cardiovascular risk [17].

Clinicians managing patients who stop Ozempic involuntarily due to shortage or cost should transition to an available GLP-1 agent where possible rather than leaving the patient without any agent [17].

Can Ozempic be combined with other medications?

Semaglutide has been studied as add-on therapy to metformin, SGLT-2 inhibitors, and basal insulin. No dose adjustment of semaglutide is required when combining with metformin or SGLT-2 inhibitors. When adding semaglutide to basal insulin, clinicians typically reduce the insulin dose by 20% to lower hypoglycemia risk, then titrate based on fasting glucose [3].

Oral semaglutide (Rybelsus, 7 mg or 14 mg daily) is a separate formulation with lower bioavailability than the injectable. It is not interchangeable with Ozempic milligram for milligram [3].

Because semaglutide delays gastric emptying, the absorption of oral medications taken concurrently may be affected. Levothyroxine and oral contraceptives are the two agents most commonly cited in clinical practice. The Ozempic prescribing information advises caution and, where possible, taking these drugs at a consistent time relative to the Ozempic dose [3].

Alcohol does not have a pharmacokinetic interaction with semaglutide, but patients on the drug often report reduced alcohol tolerance and diminished craving. The mechanism may involve GLP-1 receptor activity in the reward pathways of the brain, though direct human trial data confirming this mechanism remain limited as of 2025 [18].